Clinical trial · Interventional
Antisecretory Factor in Primary Glioblastoma 1
Antisecretory Factor, Administered as an Enriched Egg Powder, Salovum®, as Supplementary Therapy for Primary Glioblastoma During Concomitant Radio-chemotherapy.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a non-randomised, open-label, single center-centre, Phase I-II study in patients with newly diagnosed glioblastoma. 5 patients with newly diagnosed glioblastoma are enrolled in the study and will receive an egg powder enriched for antisecretory factor (AF), Salovum, daily from 2 days before concomitant radio-chemo therapy until 14 days after finalisation.The primary aim of the study is to asses safety and feasibility of this regimen.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cerebral Edema | — | UNRESOLVED | — |
| Chemotherapy Effect | — | UNRESOLVED | — |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Salovum | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Salovum
- description
- Salovum®, an egg powder enriched for anti secretory factor.
- interventionNames
- Dietary Supplement: Salovum
Primary outcomes (2)
- measure
- Number of participants with treatment-related adverse
- timeFrame
- Cumulative from day 1 to 80
- description
- Treatment related adverse events as assessed by CTCAE v 5.0
- measure
- Number of participants with completion of prescribed Salovum treatment
- timeFrame
- Cumulative from day 1 to 80
- description
- Defined as completing prescribed full Salovum treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathology verified glioblastoma 2. Age 18-69 years 3. Surgical treatment-biopsy or resection. 4. Scheduled full concomitant radiochemotherapy treatment with radiation (60 Gy) and temozolomide, 5. Informed consent Exclusion Criteria: 1. No informed consent 2. Egg yolk allergy
References
Publications (1)
- DERIVEDEhinger E, Kopecky J, Darabi A, Visse E, Edvardsson C, Tomasevic G, Cederberg D, Belting M, Bengzon J, Siesjo P. Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma. BMC Neurol. 2023 Feb 18;23(1):76. doi: 10.1186/s12883-023-03119-4. PMID 36803465